By

A mouse study of a reg­imen that erad­i­cated the bac­terium in the test tube, set­ting the stage for human trials; antibi­otic cock­tails using existing drugs; strate­gies to dis­cover new drugs...

In the first study of its kind, researchers found patients with S. aureus skin and soft tissue infections took, on average, just 57% of their prescribed antibiotic doses after leaving the hospital, resulting...

The Philippines Food and Drug Administration (FDA) announced the recall of the anti-tuberculosis drug, Onecure, after one component of the drug failed specifications. Onecure, which is manufactured by...

The U.S. Food and Drug Administration recently approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted...

The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair...

The U.S. Food and Drug Administration today approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and...

The U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational...

By

Eli Lilly and Company announced Monday that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect of ixekizumab on work productivity in patients with...

America is doing a better job of preventing healthcare-associated infections (HAIs), but more work is needed – especially in fighting antibiotic-resistant bacteria. The Centers for Disease Control and...

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving...